1009821-06-0
Chemical Structure
CX-5011 free base
- CAS No.: 1009821-06-0
- Formula:C20H12N4O2
- Molecular Weight:340.33
IUPAC Name: 5-((3-ethynylphenyl)amino)pyrimido[4,5-c]quinoline-8-carboxylic acid
InChIKey: HJGFPNFAFSFDNN-UHFFFAOYSA-N
SMILES: C#CC1=CC(NC2=NC3=CC(C(O)=O)=CC=C3C4=CN=CN=C42)=CC=C1
Biological Activity: CX-5011 free base is an ATP-competitive, selective CK2 inhibitor with an IC50 of 0.97 nM for nCK2. CX-5011 free base reduces Bin1, CKB, Tubb3, and Pxn levels. CX-5011 free base impairs myogenic differentiation, myotube formation, muscle markers, myofiber growth, and zebrafish muscle development/locomotion. CX-5011 free base can be used for breast cancer research[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CX-5011 free base | CX-5011 free base is an ATP-competitive, selective CK2 inhibitor with an IC50 of 0.97 nM for nCK2. CX-5011 free base reduces Bin1, CKB, Tubb3, and Pxn levels. CX-5011 free base impairs myogenic differentiation, myotube formation, muscle markers, myofiber growth, and zebrafish muscle development/locomotion. CX-5011 free base can be used for breast cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang R, et al. Signals from the niche promote distinct modes of translation initiation to control stem cell differentiation and renewal in the Drosophila testis. PLoS biology. 2025 Mar;23(3):e3003049.
- [2]. Battistutta R, et al. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Biochemistry. 2011 Oct 04;50(39):8478-88. [Content Brief]
- [3]. Borgo C, et al. Generation and quantitative proteomics analysis of CK2α/α’(−/−) cells. Scientific reports. 2017 Feb 17;7(1):42409.
- [4]. Salizzato V, et al. Protein kinase CK2 subunits exert specific and coordinated functions in skeletal muscle differentiation and fusogenic activity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019 Oct;33(10):10648-10667.
- [5]. Siddiqui-Jain A, et al. The discovery and characterization of CX-5011, a highly selective, potent inhibitor of Protein Kinase CK2. Cancer Research. 2008 May 1;68(9_Supplement):4875-.
- [6]. Davis-Gilbert ZW, et al. Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2. ACS medicinal chemistry letters. 2023 Apr 13;14(4):432-441. [Content Brief]
